Literature DB >> 15084121

Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain.

Ming-Rong Zhang1, Jun Maeda, Masanao Ogawa, Junko Noguchi, Takehito Ito, Yuichiro Yoshida, Takashi Okauchi, Shigeru Obayashi, Tetsuya Suhara, Kazutoshi Suzuki.   

Abstract

To develop a positron emission tomography (PET) ligand for imaging the 'peripheral benzodiazepine receptor' (PBR) in brain and elucidating the relationship between PBR and brain diseases, four analogues (4-7) of N-(2,5-dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide (2) were synthesized and evaluated as ligands for PBR. Of these compounds, fluoromethyl (4) and fluoroethyl (5) analogues had similar or higher affinities for PBR than the parent compound 2 (K(i) = 0.16 nM for PBR in rat brain sections). Iodomethyl analogue 6 displayed a moderate affinity, whereas tosyloxyethyl analogue 7 had weak affinity. Radiolabeling was performed for the fluoroalkyl analogues 4 and 5 using fluorine-18 ((18)F, beta(+); 96.7%, T(1/2) = 109.8 min). Ligands [(18)F]4 and [(18)F]5 were respectively synthesized by the alkylation of desmethyl precursor 3 with [(18)F]fluoromethyl iodide ([(18)F]8) and 2-[(18)F]fluoroethyl bromide ([(18)F]9). The distribution patterns of [(18)F]4 and [(18)F]5 in mice were consistent with the known distribution of PBR. However, compared with [(18)F]5, [(18)F]4 displayed a high uptake in the bone of mice. The PET image of [(18)F]4 for monkey brain also showed significant radioactivity in the bone, suggesting that this ligand was unstable for in vivo defluorination and was not a useful PET ligand. Ligand [(18)F]5 displayed a high uptake in monkey brain especially in the occipital cortex, a region with richer PBR than the other regions in the brain. The radioactivity level of [(18)F]5 in monkey brain was 1.5 times higher than that of [(11)C]2, and 6 times higher than that of (R)-(1-(2-chlorophenyl)-N-[(11)C]methyl,N-(1-methylpropyl)isoquinoline ([(11)C]1). Moreover, the in vivo binding of [(18)F]5 was significantly inhibited by PBR-selective 2 or 1, indicating that the binding of [(18)F]5 in the monkey brain was mainly due to PBR. Metabolite analysis revealed that [(18)F]4 was rapidly metabolized by defluorination to [(18)F]F(-) in the plasma and brain of mice, whereas [(18)F]5 was metabolized by debenzylation to a polar product [(18)F]13 only in the plasma. No radioactive metabolite of [(18)F]5 was detected in the mouse brain. The biological data indicate that [(18)F]5 is a useful PET ligand for PBR and is currently used for imaging PBR in human brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084121     DOI: 10.1021/jm0304919

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

Review 1.  Positron emission tomography imaging of neuroinflammation.

Authors:  Annachiara Cagnin; Michael Kassiou; Steve R Meikle; Richard B Banati
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

2.  Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice.

Authors:  Hiroki Takeuchi; Keiko Imamura; Bin Ji; Kayoko Tsukita; Takako Enami; Keizo Takao; Tsuyoshi Miyakawa; Masato Hasegawa; Naruhiko Sahara; Nobuhisa Iwata; Makoto Inoue; Hideo Hara; Takeshi Tabira; Maiko Ono; John Q Trojanowski; Virginia M-Y Lee; Ryosuke Takahashi; Tetsuya Suhara; Makoto Higuchi; Haruhisa Inoue
Journal:  NPJ Vaccines       Date:  2020-03-25       Impact factor: 7.344

3.  In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.

Authors:  Andrea Varrone; Patrik Mattsson; Anton Forsberg; Akihiro Takano; Sangram Nag; Balázs Gulyás; Jacqueline Borg; Ronald Boellaard; Nabil Al-Tawil; Maria Eriksdotter; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Adriaan A Lammertsma; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

4.  Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102 and [18F]PBR111.

Authors:  S Eberl; A Katsifis; M A Peyronneau; L Wen; D Henderson; C Loc'h; I Greguric; J Verschuer; T Pham; P Lam; F Mattner; A Mohamed; M J Fulham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-04       Impact factor: 9.236

5.  [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain.

Authors:  S Lavisse; K Inoue; C Jan; M A Peyronneau; F Petit; S Goutal; J Dauguet; M Guillermier; F Dollé; L Rbah-Vidal; N Van Camp; R Aron-Badin; P Remy; P Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-12-09       Impact factor: 9.236

Review 6.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers.

Authors:  Fabien Chauveau; Hervé Boutin; Nadja Van Camp; Frédéric Dollé; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

7.  Regulation of Anxiety and Depression by Mitochondrial Translocator Protein-Mediated Steroidogenesis: the Role of Neurons.

Authors:  Anna M Barron; Makoto Higuchi; Satoko Hattori; Seiji Kito; Tetsuya Suhara; Bin Ji
Journal:  Mol Neurobiol       Date:  2020-09-29       Impact factor: 5.590

8.  Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation.

Authors:  Masahiro Fujita; Masao Imaizumi; Sami S Zoghbi; Yota Fujimura; Amanda G Farris; Tetsuya Suhara; Jinsoo Hong; Victor W Pike; Robert B Innis
Journal:  Neuroimage       Date:  2007-11-22       Impact factor: 6.556

Review 9.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.

Authors:  Richard J Perrin; Anne M Fagan; David M Holtzman
Journal:  Nature       Date:  2009-10-15       Impact factor: 49.962

Review 10.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.